CGEM — Cullinan Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $518.74m
- $119.76m
- 30
- 42
- 16
- 19
Annual cashflow statement for Cullinan Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -59.5 | -67.5 | 109 | -155 | -168 |
| Depreciation | |||||
| Non-Cash Items | 22.8 | 27.5 | -247 | 20.9 | 22.4 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 6.85 | -3.54 | 11.2 | -0.339 | -0.389 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -29.8 | -43.4 | -127 | -134 | -145 |
| Capital Expenditures | -0.01 | 0 | -1.13 | -0.208 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -5.41 | -334 | 250 | 36 | -136 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -5.42 | -334 | 249 | 35.8 | -136 |
| Financing Cash Flow Items | 0.993 | -1.76 | -32.1 | 0 | -4.45 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 140 | 269 | -25.9 | 40.8 | 266 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 105 | -108 | 96.4 | -57.7 | -15.4 |